Subscribe
designer491
designer491 / iStockphoto.com
19 January 2018Americas

Mylan opposes Allergan’s attempted withdrawal from Restasis IPRs

Generics company Mylan Pharmaceuticals has resisted Allergan’s attempt to withdraw itself from a series of inter partes reviews (IPRs) relating to patents covering dry-eye medication Restasis (cyclosporine ophthalmic emulsion).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.
Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.
Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

More on this story

Americas
Allergan deal with tribe could kill off IPR: Bryson
17 October 2017   A US judge has said Allergan’s controversial patent licensing deal with a Native American tribe could spell the end for the inter partes review.
Big Pharma
Allergan tries to escape Restasis IPRs
10 January 2018   Allergan is attempting to remove itself from a series of inter partes reviews focused on dry eye treatment Restasis (cyclosporine ophthalmic emulsion).

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?